Eli Lilly and Company (LLY) : Money flow in the Eli Lilly and Company (LLY) stock was negative (5.62 million) on Wednesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $2.3 million, compared to $7.92 million on downticks. The total uptick to downtick ratio was 0.29, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($5.94 million), indicating selling on the strength. Downtick transaction value in block trades amounted to $5.94 million, indicating persistent selling. Eli Lilly and Company (LLY) traded $0.2 higher at $81.08 gaining 0.25% over the previous days close.
Eli Lilly and Company has dropped 0.2% in the last five trading days, however, the shares have posted positive gains of 2.68% in the last 4 weeks. Eli Lilly and Company is up 3.93% in the last 3-month period. Year-to-Date the stock performance stands at -2.28%.
Eli Lilly and Company (LLY) : The consensus on Eli Lilly and Company (LLY) based on 15 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 11 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Eli Lilly and Company (NYSE:LLY): stock was range-bound between the intraday low of $80.02 and the intraday high of $81.17 after having opened at $80.84 on Wednesdays session. The stock finally closed in the red at $80.84, a loss of -0.21%. The stock remained in the red for the whole trading day. The total traded volume was 2,467,803 shares. The stock failed to cross $81.17 in Wednesdays trading. The stocks closing price on Thursday was $80.88.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.